Hyperkalaemia Clinical Trial
Official title:
A Two-Cohort, Randomised Sequence, Cross-over, Open-label Study to Assess the Effect of a Single Dose of Sodium Zirconium Cyclosilicate (SZC) on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy Subjects
This study will be an open-label, randomised sequence, 2-period, 2-cohort, 2-treatment in each cohort, cross-over study in healthy subjects (males and females of non-childbearing potential), performed at a single study centre.
The study will comprise: - A screening period of maximum 28 days; - Two treatment periods: - Treatment Period 1 starts with admission to the Clinical Unit on Day -1, followed by dosing on Day 1 with the assigned treatment (A, B, C, or D) as per assigned cohort and treatment sequence, followed by a washout period of at least 14 days. - Treatment Period 2 starts with admission to Clinical Unit on Day -1, followed by dosing on Day 1 with cross-over treatment as per assigned cohort, followed by a follow-up period of 7 to 10 days. - A follow-up visit/early termination visit at 7 to 10 days after the last investigation medicinal product (IMP) administration. Subjects will be assigned to either Cohort 1 (tacrolimus) or to Cohort 2 (cyclosporin). Each cohort will have 2 treatment periods. Subjects in each cohort will be randomly assigned to one of 2 treatment sequences (AB|BA or CD|DC) where, - Treatment A: Tacrolimus - Treatment B: Tacrolimus + SZC - Treatment C: Cyclosporin - Treatment D: Cyclosporin + SZC ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04676646 -
Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone
|
Phase 4 | |
| Recruiting |
NCT05347693 -
Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study
|
Phase 4 | |
| Active, not recruiting |
NCT05271266 -
A Multicenter, Prospective, Non-interventional Cohort Study to Evaluate the Safety and Treatment Pattern of Sodium Zirconium Cyclosilicate for Hyperkalaemia Management in Real World Practice in China
|
||
| Terminated |
NCT04727528 -
Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease
|
Phase 3 | |
| Recruiting |
NCT04249648 -
Hyperkalaemia and Its Impact on Therapy With RAASi
|
||
| Recruiting |
NCT06185660 -
A National, Multicenter, Prospective, Observational Study to Assess Patient Characteristics, Treatment Algorithms and Disease Management of Hyperkalaemia Patients With Chronic Kidney Disease or Under Dialysis or With Heart Failure, Treated With Sodium Zirconium Cyclosilicate in Greece
|
||
| Completed |
NCT05462119 -
Safety of Oral Resin for Treatment of Hyperkalemia in Chinese Patients With Renal Insufficiency
|
||
| Terminated |
NCT04997161 -
Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With Hyperkalaemia
|
Phase 4 | |
| Recruiting |
NCT03813407 -
An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia
|
Phase 3 |